- Home
- FENC
as 11-14-2025 3:45pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 234.9M | IPO Year: | 2001 |
| Target Price: | $13.50 | AVG Volume (30 days): | 69.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $9.92 | Next Earning Date: | 11-13-2025 |
| Revenue: | $38,790,000 | Revenue Growth: | -21.39% |
| Revenue Growth (this year): | -4.51% | Revenue Growth (next year): | 64.79% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Nov 5 '25 | Sell | $8.10 | 10,000 | $81,000.00 | 82,318 | |
| RALLIS CHRIS A | FENC | Director | Oct 10 '25 | Sell | $9.24 | 1,775 | $16,401.00 | 57,079 | |
| Southpoint Capital Advisors LP | FENC | 10% Owner | Oct 9 '25 | Sell | $9.35 | 20,609 | $192,613.77 | 4,010,100 | |
| Southpoint Capital Advisors LP | FENC | 10% Owner | Oct 8 '25 | Sell | $9.47 | 19,605 | $185,722.09 | 4,010,100 | |
| Southpoint Capital Advisors LP | FENC | 10% Owner | Oct 7 '25 | Sell | $9.59 | 26,900 | $257,892.99 | 4,010,100 | |
| Raykov Rosty | FENC | Director | Oct 6 '25 | Sell | $9.78 | 10,000 | $97,800.00 | 82,318 | |
| Raykov Rosty | FENC | Director | Sep 4 '25 | Sell | $8.92 | 10,000 | $89,200.00 | 82,318 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Wedbush Says Fennec's Q3 Revenue Beats Estimates, Backs Outperform Rating
MT Newswires
a day ago
Fennec Pharmaceuticals Prices US$35 Million Share Offering at US$7.50
GlobeNewswire
2 days ago
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
GlobeNewswire
2 days ago
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
Zacks
2 days ago
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
MT Newswires
2 days ago
Fennec Pharmaceuticals Q3 Loss Narrows as Pedmark Sales Hit Record
GlobeNewswire
2 days ago
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
GlobeNewswire
2 days ago
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.